Latest Germany News

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.

Altech Batteries has reported a significant technical milestone with its Silumina Anodes™ technology achieving 88.5% capacity retention after 500 cycles, alongside a $6 million capital raise and a strategic board renewal focused on commercialisation.

Sprintex Limited has secured its largest-ever €15.6 million purchase order with Mest Water, marking a pivotal shift from technology validation to commercial deployment. Supported by favourable European regulations and expanding markets in India, the company is poised for sustained revenue growth.

AML3D Limited has reported a remarkable 360% increase in customer receipts for the December 2025 quarter, driven by strong demand from the US defence sector and a robust order book of A$16.5 million for FY26. The company is accelerating its US scale-up strategy while expanding into UK and European defence markets.

Elsight Limited capped 2025 with record quarterly revenue and a substantial US$21.2 million contract, signalling robust growth and expanding global defence engagements heading into 2026.

Vulcan Energy has reported strong production test results from its LSC-1b sidetrack well, reinforcing the viability of its Phase One Lionheart lithium project in Germany. The well’s performance supports the project’s ambitious lithium and renewable energy production targets.

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.

PolyNovo reports a robust 26% increase in group sales for 1H FY26, driven by strong U.S. market expansion and a near tripling of NovoSorb MTX sales. The company also completes a new manufacturing facility, positioning itself for sustained growth.

Talga Group has entered a strategic development agreement with German battery innovator V4Smart to co-develop high-performance graphite anodes for fast-charging lithium-ion batteries, aiming for commercial readiness by 2027.

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.